Skip to main content

Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate

Buy Article:

$43.00 plus tax (Refund Policy)

Imatinib mesylate (IM) is currently used as the first therapeutic choice against chronic myelogenous leukaemia (CML). Because IM poorly penetrates the blood‐brain barrier, IM‐treated CML patients may have a potential risk of central nervous system (CNS) involvement. Here we report a case with lymphoid blast crisis isolated only in CNS after bacterial meningitis, although the patient achieved and maintained complete cytogenetic response by IM therapy. It is important to consider isolated CNS blast crisis as a possible event in IM‐treated CML patients.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: blast crisis; central nervous system; chronic myelogenous leukaemia; imatinib mesylate

Document Type: Research Article

Affiliations: Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan

Publication date: 2009-06-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more